Recent advances in micro/nanotechnologies for global control of hepatitis B infection

Biotechnology Advances

Volumn 33, Issue 1, 2015, Pages 178-190

  Yildiz, U Hakan ^a   Inci, Fatih ^a   Wang, ShuQi ^a   Toy, Mehlika ^a   Tekin, H Cumhur ^a   Javaid, Asad ^b   Lau, Daryl T Y ^b   Demirci, Utkan ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Diagnosis; Graphene; Hepatitis B; Microfluidic; Nanobiotechnology; Nanotechnology; Plasmonics; Point of care; Screening

Indexed keywords

DEVELOPING COUNTRIES; DIAGNOSIS; GRAPHENE; METAL NANOPARTICLES; MICROANALYSIS; MICROFABRICATION; MICROFLUIDICS; NANOBIOTECHNOLOGY; SCREENING; VIRUSES; YARN;

HEALTHCARE INFRASTRUCTURE; HEPATITIS B; MICRO-FABRICATION TECHNOLOGY; MICRO-FLUIDIC DEVICES; MICROFABRICATION PROCESS; NEW GENERATION METHODOLOGIES; PLASMONICS; POINT OF CARE;

NANOTECHNOLOGY;

DEVELOPING WORLD; HEPATITIS; INFECTIOUS DISEASE; NANOTECHNOLOGY; VIRAL DISEASE;

HEPATITIS B VIRUS;

BIOMATERIAL;

CHEMISTRY; DEVELOPING COUNTRY; ECONOMICS; GROWTH, DEVELOPMENT AND AGING; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; ISOLATION AND PURIFICATION; LAB ON A CHIP; MICROTECHNOLOGY; NANOTECHNOLOGY; PREVALENCE; PROCEDURES; PUBLIC HEALTH;

BIOCOMPATIBLE MATERIALS; DEVELOPING COUNTRIES; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAB-ON-A-CHIP DEVICES; MICROTECHNOLOGY; NANOTECHNOLOGY; PREVALENCE; PUBLIC HEALTH;

EID: 84922827498     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2014.11.003     Document Type: Review

References (111)

1. Allain J.P. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 2004, 86:83-91.
2. Arlett J.L., Myers E.B., Roukes M.L. Comparative advantages of mechanical biosensors. Nat Nanotechnol 2011, 6:203-215.
3. Ba Alawi F., Robertson P.W., LePage A.K., Jayamaha J., Baleriola C., Rawlinson W.D. The reliability of HBV core antibody in serological screening for hepatitis B virus. Pathology 2013, 45:501-505.
4. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001-1010.
5. Chang T.T., Lai C.L., Kew Yoon S., Lee S.S., Coelho H.S., Carrilho F.J., et al. Entecavir treatment for up to 5years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010, 51:422-430.
6. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
7. Chen C.J., Iloeje U.H., Yang H.I. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007, 11:797-816. [viii].
8. Chen L., Zhang X., Zhou G., Xiang X., Ji X., Zheng Z., et al. Simultaneous determination of human Enterovirus 71 and Coxsackie virus B3 by dual-color quantum dots and homogeneous immunoassay. Anal Chem 2012, 84:3200-3207.
9. Chevaliez S., Rodriguez C., Pawlotsky J.M. New virologic tools for management of chronic hepatitis B and C. Gastroenterology 2012, 142:1303-1313. [e1].
10. Chien R.N., Liaw Y.F. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res 2008, 22:1081-1092.
11. Cho Y.K., Kim J., Lee Y., Kim Y.A., Namkoong K., Lim H., et al. Clinical evaluation of micro-scale chip-based PCR system for rapid detection of hepatitis B virus. Biosens Bioelectron 2006, 21:2161-2169.
12. Chou R., Dana T., Bougatsos C., Blazina I., Zakher B., Khangura J. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: systematic review to update the 2004 US Preventive Services Task Force recommendation. Ann Intern Med 2014, 161(1):31-45.
13. Chuang T.L., Chang C.C., Chu-Su Y., Wei S.C., Zhao X.H., Hsueh P.R., et al. Disposable surface plasmon resonance aptasensor with membrane-based sample handling design for quantitative interferon-gamma detection. Lab Chip 2014, 14:2968-2977.
14. Chuanga Tsung-Liang, Weib Shih-Chung, Leec Szu-Yuan, Lina Chii-Wann A polycarbonate based surface plasmon resonance sensing cartridge for high sensitivity HBV loop-mediated isothermal amplification. Biosens Bioelectron 2012, 32:89-95.
15. Cohen C., Holmberg S.D., McMahon B.J., Block J.M., Brosgart C.L., Gish R.G., et al. Is chronic hepatitis B being undertreated in the United States?. J Viral Hepat 2011, 18:377-383.
16. Colonno R.J., Rose R., Baldick C.J., Levine S., Pokornowski K., Yu C.F., et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006, 44:1656-1665.
17. Cooper C.L., Mills E., Wabwire B.O., Ford N., Olupot-Olupot P. Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa. Int J Infect Dis 2009, 13:302-306.
18. Delaney W.E. Molecular virology of chronic hepatitis B and C: parallels, contrasts and impact on drug development and treatment outcome. Antiviral Res 2013, 99:34-48.
19. Dey D., Goswami T. Optical biosensors: a revolution towards quantum nanoscale electronics device fabrication. J Biomed Biotechnol 2011, 2011:348218.
20. Dienstag J.L. Hepatitis B, virus infection. N Engl J Med 2008, 359:1486-1500.
21. Doo E., Liang T.J. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001, 120:1000-1008.
22. El-Ghitany E.M., Farghaly A.G. Evaluation of commercialized rapid diagnostic testing for some hepatitis B biomarkers in an area of intermediate endemicity. J Virol Methods 2013, 194:190-193.
23. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142:1264-1273. [e1].
24. Fernandez-Montero J.V., Soriano V. Management of hepatitis C in HIV and/or HBV co-infected patients. Best Pract Res 2012, 26:517-530.
25. Ferreira R., et al. Acute hepatitis induced by fosfomycin: a case report and review of the literature. GE Jornal Português de Gastrenterologia 2012, 19(5):263-266.
26. Gish R.G. Chronic hepatitis B viral infection. Text book Gastroenterol 2008, 2:2112.
27. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005, 352:2673-2681.
28. Harper S.J., Ward L.I., Clover G.R. Development of LAMP and real-time PCR methods for the rapid detection of Xylella fastidiosa for quarantine and field applications. Phytopathology 2010, 100:1282-1288.
29. Heathcote E.J., Marcellin P., Buti M., Gane E., De Man R.A., Krastev Z., et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011, 140:132-143.
30. Heller Iddo, Kong Jing, Heering Hendrik A., Williams Keith A., Lemay Serge G., Dekker C. Individual single-walled carbon nanotubes as nanoelectrodes for electrochemistry. Nano Lett 2005, 5:137-142.
31. Hoffmann C.J., Thio C.L. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007, 7:402-409.
32. Hollinger F.B., Lau D.T. Hepatitis B: the pathway to recovery through treatment. Gastroenterol Clin North Am 2006, 35:895-931.
33. Homola J. Surface plasmon resonance sensors for detection of chemical and biological species. Chem Rev 2008, 108:462-493.
34. Hoofnagle J.H. Hepatitis B-preventable and now treatable. N Engl J Med 2006, 354:1074-1076.
35. Hunt C.M., McGill J.M., Allen M.I., Condreay L.D. Clinical relevance of hepatitis B viral mutations. Hepatology 2000, 31:1037-1044.
36. Hwang S.Y., Yoo C.H., Jeon J.Y., Choi S.C., Lee E.K. Quantitative assay of hepatitis B surface antigen by using surface plasmon resonance biosensor. Biotechnol Bioproc Eng 2005, 10:309-314.
37. Iloeje U.H., Yang H.I., Jen C.L., Su J., Wang L.Y., You S.L., et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007, 5:921-931.
38. Inci F., Tokel O., Wang S., Gurkan U.A., Tasoglu S., Kuritzkes D.R., et al. Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood. ACS Nano 2013, 7:4733-4745.
39. Jung Jae Hwan, D.S.C., Liu Fei, Lee Kang Bum, Seo Tae Seok A graphene oxide based immuno-biosensor for pathogen detection. Angew Chem Int Ed 2010, 49:5708-5711.
40. Jung J.H., Cheon D.S., Liu F., Lee K.B., Seo T.S. A graphene oxide based immuno-biosensor for pathogen detection. Angew Chem 2010, 49:5708-5711.
41. Kamisango K., Kamogawa C., Sumi M., Goto S., Hirao A., Gonzales F., et al. Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. J Clin Microbiol 1999, 37:310-314.
42. Kierny M.R., Cunnningham T.D., Kay B.K. Detection of biomarkers using recombinant antibodies coupled to nanostructured platforms. Nano Rev 2012, 3:17240.
43. Kim J.H., Yu S.K., Seo Y.S., Yim H.J., Yeon J.E., Park J.J., et al. Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy. J Gastroenterol Hepatol 2007, 22:1220-1225.
44. Kim Y., Moon S., Kuritzkes D., Demirci U. Quantum dot-based HIV capture and imaging in a microfluidic channel. Biosens Bioelectron 2009, 25:253-258.
45. Kwon O.S., Lee S.H., Park S.J., An J.H., Song H.S., Kim T., et al. Large-scale graphene micropattern nano-biohybrids: high-performance transducers for FET-type flexible fluidic HIV immunoassays. Adv Mater 2013, 25:4177-4185.
46. Lai C.L., Yuen M.F. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 2013, 57:399-408.
47. Lai C.L., Chien R.N., Leung N.W., Chang T.T., Guan R., Tai D.I., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998, 339:61-68.
48. Lai C.L., Shouval D., Lok A.S., Chang T.T., Cheinquer H., Goodman Z., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011-1020.
49. Lau D.T., Khokhar M.F., Doo E., Ghany M.G., Herion D., Park Y., et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000, 32:828-834.
50. Lavanchy D. Hepatitis B, virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107.
51. Lee C.M., Chen C.H., Lu S.N., Tung H.D., Chou W.J., Wang J.H., et al. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol 2003, 38:95-101.
52. Lee S.Y., Lee C.N., Mark H., Meldrum D.R., Lin C.W. Efficient, specific, compact hepatitis B diagnostic device: optical detection of the hepatitis B virus by isothermal amplification. Sensors Actuators B Chem 2007, 127:598-605.
53. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531.
54. Liaw Y.F., Kao J.H., Piratvisuth T., Chan H.L.Y., Chien R.N., Liu C.J., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012, 6:531-561.
55. Lissandrello C., Inci F., Francom M., Paul M.R., Demirci U., Ekinci K.L. Nanomechanical motion of Escherichia coli adhered to a surface. Appl Phys Lett 2014, 105:113701.
56. Liu F., Choi K.S., Park T.J., Lee S.Y., Seo T.S. Graphene-based electrochemical biosensor for pathogenic virus detection. Biochip J 2011, 5:123-128.
57. Liu X., Wang F., Aizen R., Yehezkeli O., Willner I. Graphene oxide/nucleic-acid-stabilized silver nanoclusters: functional hybrid materials for optical aptamer sensing and multiplexed analysis of pathogenic DNAs. J Am Chem Soc 2013, 135:11832-11839.
58. Liver EAFTSOT EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185.
59. Locarnini S., Mason W.S. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006, 44:422-431.
60. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
61. Lou S.C., Pearce S.K., Lukaszewska T.X., Taylor R.E., Williams G.T., Leary T.P. An improved Abbott ARCHITECT assay for the detection of hepatitis B virus surface antigen (HBsAg). J Clin Virol 2011, 51:59-63.
62. Magnius L.O., Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995, 38:24-34.
63. Mannoor M.S., Tao H., Clayton J.D., Sengupta A., Kaplan D.L., Naik R.R., et al. Graphene-based wireless bacteria detection on tooth enamel. Nat Commun 2012, 3:763.
64. Marcellin P., Heathcote E.J., Buti M., Gane E., de Man R.A., Krastev Z., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359:2442-2455.
65. Marcellin P., Gane E., Buti M., Afdhal N., Sievert W., Jacobson I.M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013, 381:468-475.
66. McMahon B.J. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 2009, 334-342.
67. McMahon B.J. The natural history of chronic hepatitis B virus infection. Hepatology 2009, 49:S45-S55.
68. Mori Y., Notomi T. Loop-mediated isothermal amplification (LAMP): a rapid, accurate, and cost-effective diagnostic method for infectious diseases. J Infect Chemother 2009, 15:62-69.
69. Moskovitz D.N., Osiowy C., Giles E., Tomlinson G., Heathcote E.J. Response to long-term lamivudine treatment (up to 5years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat 2005, 12:398-404.
70. Notomi T., Okayama H., Masubuchi H., Yonekawa T., Watanabe K., Amino N., et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res 2000, 28:E63.
71. Okamoto H., Yotsumoto S., Akahane Y., Yamanaka T., Miyazaki Y., Sugai Y., et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990, 64:1298-1303.
72. Okamoto H., Tsuda F., Akahane Y., Sugai Y., Yoshiba M., Moriyama K., et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994, 68:8102-8110.
73. Palek E., Fojta M. Peer reviewed: detecting DNA hybridization and damage. Anal Chem 2001, 73:74 A-83 A.
74. Papatheodoridis G.V., Dimou E., Dimakopoulos K., Manolakopoulos S., Rapti I., Kitis G., et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005, 42:121-129.
75. Pawlotsky J.M., Dusheiko G., Hatzakis A., Lau D., Lau G., Liang T.J., et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008, 134:405-415.
76. Rehermann Barbara, Nascimbeni Michelina Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005, 5(3):215-229.
77. Scheiblauer H., El-Nageh M., Diaz S., Nick S., Zeichhardt H., Grunert H.P., et al. Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes. Vox Sang 2010, 98:403-414.
78. Sevimli S.I.F., Zareie H., Bulmus V. Well-defined cholesterol polymers with pH-controlled membrane switching activity. Biomacromolecules 2012, 13:3064-3075.
79. Shafiee H., Jahangir M., Inci F., Wang S., Willenbrecht R.B., Giguel F.F., et al. Acute on-chip HIV detection through label-free electrical sensing of viral nano-lysate. Small 2013, 9:2553-2563.
80. Shafiee H., Lidstone E.A., Jahangir M., Inci F., Hanhauser E., Henrich T.J., et al. Nanostructured optical photonic crystal biosensor for HIV viral load measurement. Sci Rep 2014, 4:4116.
81. Shen Y.C., Hsu C., Cheng C.C., Hu F.C., Cheng A.L. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression. Oncology 2012, 82:275-289.
82. Sherry L.J., Chang S.H., Schatz G.C., Van Duyne R.P., Wiley B.J., Xia Y.N. Localized surface plasmon resonance spectroscopy of single silver nanocubes. Nano Lett 2005, 5:2034-2038.
83. Snow-Lampart A., Chappell B., Curtis M., Zhu Y., Myrick F., Schawalder J., et al. No resistance to tenofovir disoproxil fumarate detected after up to 144weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011, 53:763-773.
84. Soldatkin A.P., Montoriol J., Sant W., Martelet C., Jaffrezic-Renault N. A novel urea sensitive biosensor with extended dynamic range based on recombinant urease and ISFETs. Biosens Bioelectron 2003, 19:131-135.
85. Star A., Tu E., Niemann J, Gabriel J-CP, Joiner C.S., Valcke a.C. Label-free detection of DNA hybridization using carbon nanotube network field-effect transistors. Proc Natl Acad Sci U S A 2006, 103:921-926.
86. Stramer S.L., Wend U., Candotti D., Foster G.A., Hollinger F.B., Dodd R.Y., et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011, 364:236-247.
87. Tacke F., Gehrke C., Luedde T., Heim A., Manns M.P., Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol 2004, 78:8524-8535.
88. Tang D.P., Tang J., Su B.L., Ren J.J., Chen G.N. Simultaneous determination of five-type hepatitis virus antigens in 5min using an integrated automatic electrochemical immunosensor array. Biosens Bioelectron 2010, 25:1658-1662.
89. Tenney D.J., Rose R.E., Baldick C.J., Pokornowski K.A., Eggers B.J., Fang J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5years of therapy. Hepatology 2009, 49:1503-1514.
90. Tokel O., Inci F., Demirci U. Advances in plasmonic technologies for point of care applications. Chem Rev 2014, 114:5728-5752.
91. Tomita N., Mori Y., Kanda H., Notomi T. Loop-mediated isothermal amplification (LAMP) of gene sequences and simple visual detection of products. Nat Protoc 2008, 3:877-882.
92. Toy M. Cost-effectiveness of viral hepatitis B & C treatment. Best Pract Res 2013, 27:973-985.
93. Tuma P., Medrano J., Resino S., Vispo E., Madejon A., Sanchez-Piedra C., et al. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. Antivir Ther 2010, 15:881-886.
94. Tung J.S., Gimenez J., Przysiecki C.T., Mark T. Characterization of recombinant Hepatitis B surface antigen using surface plasmon resonance. J Pharm Sci 1998, 87(1):76-80.
95. Wang S., Xu F., Demirci U. Advances in developing HIV-1 viral load assays for resource-limited settings. Biotechnol Adv 2010, 28:770-781.
96. Wang X., Li Y., Wang H., Fu Q., Peng J., Wang Y., et al. Gold nanorod-based localized surface plasmon resonance biosensor for sensitive detection of hepatitis B virus in buffer, blood serum and plasma. Biosens Bioelectron 2010, 26:404-410.
97. Wang S., Inci F., Chaunzwa T.L., Ramanujam A., Vasudevan A., Subramanian S., et al. Portable microfluidic chip for detection of Escherichia coli in produce and blood. Int J Nanomedicine 2012, 7:2591-2600.
98. Wang S., Sarenac D., Chen M.H., Huang S.H., Giguel F.F., Kuritzkes D.R., et al. Simple filter microchip for rapid separation of plasma and viruses from whole blood. Int J Nanomedicine 2012, 7:5019-5028.
99. Wang S., Esfahani M., Gurkan U.A., Inci F., Kuritzkes D., Demirci U. Efficient on-chip isolation of HIV subtypes. Lab Chip 2012, 12:1508-1515.
100. Wang S., Li L., Jin H.L., Yang T., Bao W.W., Huang S.M., et al. Electrochemical detection of hepatitis B and papilloma virus DNAs using SWCNT array coated with gold nanoparticles. Biosens Bioelectron 2013, 41:205-210.
101. Wang S., Inci F., De Libero G., Singhal A., Demirci U. Point-of-care assays for tuberculosis: role of nanotechnology/microfluidics. Biotechnol Adv 2013, 31:438-449.
102. Wang S.T.S., Chen P.Z., Chen M., Akbas R., Wach S., Ozdemir C.I., et al. Micro-a-fluidics ELISA for rapid CD4 cell count at the point-of-care. Sci Rep 2014, 4:3796.
103. Weinbaum C.M., Williams I., Mast E.E., Wang S.A., Finelli L., Wasley A., et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008, 57:1-20.
104. WHO vaccine-preventable diseases: monitoring system, in 2013 global summary. Geneva.
105. Wilson J.M., Jungner Y.G. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 1968, 65:281-393.
106. Wynne S.A., Crowther R.A., Leslie A.G.W. The crystal structure of the human hepatitis B virus capsid. Mol Cell 1999, 3:771-780.
107. Ye Y.K., Zhao J.H., Yan F., Zhu Y.L., Ju H.X. Electrochemical behavior and detection of hepatitis B virus DNA PCR production at gold electrode. Biosens Bioelectron 2003, 18:1501-1508.
108. Yuen M.F., Lai C.L. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol 2011, 26(Suppl. 1):138-143.
109. Zanetti A.R., Van Damme P., Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008, 26:6266-6273.
110. Zhang C., Xu J., Zhang S., Ji X., He Z. One-pot synthesized DNA-CdTe quantum dots applied in a biosensor for the detection of sequence-specific oligonucleotides. Chemistry 2012, 18:8296-8300.
111. Zhang W., Li F., Hu Y., Gan S., Han D., Zhang Q., Li Niu Perylene derivative-bridged Au-graphene nanohybrid for label-free HpDNA biosensor. J Mater Chem B 2014, 2:3142-3148.